On the other hand, by performing PPI with putative PD therapeutic targets, we found PPI network exists between significant risk genes and anti-parkinsonism drug targets, such as CTSB and DGKQ can interact with the dopamine network with SNCA, and CD38, CD84, FCGR2A, FCGR2B, and ENTPID could interact with the dopamine network ADORA2A (Fig. 2b). This evidence concerns the gene FCGR2A and Parkinson disease.